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Outline
• Life without LPS 
– Is it possible?
– How?
• Making it irreversible
• Characterizing LPS-free strains
• Potential applications for vaccines
• Crabs
2
The cell envelope of Gram-negative bacteria
~2 x 106 LPS molecules 
per cell 
30% of the total outer 
membrane gross weight.
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Inner and Outer Membrane Components 
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The challenge of endotoxin removal from biological samples
Method Disadvantages
Ultrafiltration • Only useful for small proteins.
• Would fail if interactions between endotoxin and proteins cause
endotoxin monomers to permeate with proteins through the membrane. 
• Inefficient for proteins which can be damaged by physical forces.
Activated carbon • Adsorbing activity for both endotoxin and protein.
Surfactants • Expensive, would add significant costs to a manufacturing process. 
• May affect the bioactivity of the protein of interest.
• Certain amounts of surfactant always remain in the protein solution.
Removal may lead to product loss.
Anion-exchange chromatography • Adsorbing capacity is high for both endotoxin and acidic protein.
• No selectivity to adsorb endotoxin.
Histamine- and histidine-
immobilized Sepharose
• Removing capacity dependent on the ionic strength.
• Biological activity of histamine.
Polymyxin B-immobilized 
Sepharose
• Protein losses due to the ionic interaction between the cationic region of
polymyxin B and net-negatively charged proteins at low ionic strength.
• Polymixin B is physiologically active.
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E. coli Kdo2-LipidA Structure
Simplified E. coli Kdo2-LipidA Structure
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Synthesis of Kdo2-LipidA
Lipid IVA
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Addition of A5P Restores Kdo Synthesis in kdsD gutQ 
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Suppressors in Gene yhjD Identified
Selected by “weaning” ∆gutQ ∆kdsD off A5P
Gain of function:  Can’t delete yhjD as suppressor
Also msbA Suppressors in KPM22-like Mutants
P18S P50S
Mamat, U. et al. (2008) Mol Microbiol 67: 633-648. 
The Essential Transporter MsbA is Highly Selective for Hexa-
Acylated Lipid A/LPS
Lipid A
Stimulation of MsbA ATPase activity in proteoliposomes 
Lipid IVA
Doerrler, W.T. and Raetz, C.R.H. (2002) J Biol Chem 277: 36697-36705.
Schematic architecture of the lipopolysaccharide 
of Gram-negative bacteria
QA/QC QA/QC
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Synthesized Inner Surface Inner MembraneAdded in Periplasm
Location of single amino acid substitutions in MsbA suppressor proteins of
FreE coli™ strains KPM22 L1 and KPM22 L11
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Mamat, U. et al. (2008) Mol Microbiol 67: 633-648. 
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Growth of non-conditional Kdo-pathway mutants at 37°C in LB medium
E. coli strain Doubling time [min]
BW30270 wt 24
KPM22 40
KPM22 L1 37
KPM22 L11 39
KPM22 L13 59
KPM22 L14 44
KPM22 L15 40
KPM22 L18 36
KPM22 L20 55
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Charge deconvoluted electrospray
ionization Fourier transform ion
cyclotron (ESI FT-ICR) mass spectra
in negative ion mode of purified LPS
samples from E. coli BW30270 (A),
and FreE coli™ strains KPM22 (B) and 
KPM25 (C)
The predominant LPS-related peak
Meredith, T.C. et al. (2006) ACS Chem Biol 1: 33-42. 
in KPM22 is the precursor lipid IVA.
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Prevent Regaining of LPS
Construction of E. coli derivatives that 
- Entirely lack LPS 
- Cannot regain the ability to synthesize active LPS
- Viable, able to grow exponetially
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Construction of FreE coli™ KPM318 
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ESI FT-ICR mass spectra in negative ion mode of LPS samples isolated from 
FreE coli™ strains KPM316 (A) and KPM318 (B)
m = 1527.86 u
m = 1404.86 u
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Human TLR4/MD2 Assays
• HEK-Blue cell line based
– Overexpressing TLR4/MD2
– Phosphatase reporter gene linked to NFkappaB
• HEK line independently expressing TLR4/MD2
– IL-8 secretion monitored
• Human macrophages – primary isolates from 
subjects
– TNF-alpha production measured
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The bacterial cells (A) and the LPS/lipid IVA (B) of FreE coli™ KPM318 are 
virtually free of hTLR4/MD2-stimulating activity
A.  Whole Bacterial Cells in Assay B.  Outer Membrane Extracts in Assay
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Stimulation of human macrophages and HEK293 hTLR4/MD2 #33 Cells by 
LPS/lipid IVA of FreE coli™ KPM318 
A.   Macrophages B.  HEK293-hTLR4/MD-2
10 ng 10 ng
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10 µg
10 µg
Growth of FreE coli™ KPM318 and temperature-resistant FreE coli™ KPM318 
derivatives at 42°C in SB medium
Strain Doubling time [min]
KPM318 -
KPM334 93
KPM335 86
KPM336 100
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Scanning electron micrographs of FreE coli™ KPM318 and
temperature-resistant FreE coli™ KPM318 derivatives
2 µm
KPM318
2 µm
BW30270
2 µm
KPM335
2 µm
KPM336
Electron micrographs by Manfred Rohde, Helmholtz Center for Infection Research, Braunschweig, Germany.
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Potential applications of the LPS-free strains:
Hosts for protein expression
- research e.g. variant screening, phage display output,
- manufacturing, reducing DSP costs
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Hosts for plasmid DNA preparation
- research e.g. for transient transfection of HEK293 cells
- production of DNA vaccine
Modify Gram negative pathogens to be LPS-free
FreE coli™ strains KPM318 and KPM335 as hosts for endotoxin-free protein 
production:  Expression and purification ApoA1
mAU
BW30270/pJexpress404:CYT-APOA1H6 (control)
KPM318/pJexpress404:CYT-APOA1H6
KPM335/pJexpress404:CYT-APOA1H6
Flow-through
500 mM imidazole
peak
Elution volume
80 mM imidazole
peak
IMAC on HisTrap HP (1 ml) columns 29
FreE coli™ strains KPM318 and KPM335 as hosts for endotoxin-free protein 
production:  Expression and purification ApoA1
BW30270/pJexpress404:CYT-APOA1H6 (control)
KPM335/pJexpress404:CYT-APOA1H6
KPM318/pJexpress404:CYT-APOA1H6
1. Insoluble cell fraction
2. Whole-cell lysate
3. Cleared cell lysate
4. IMAC flow-through
5. IMAC 80 mM imidazole peak
6. IMAC 80 mM imidazole peak
7. IMAC 500mM imidazole peak
8. IMAC 500mM imidazole peak
9. IMAC 500mM imidazole peak
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Expression and purification of ApoA1:  Stimulation of HEK-Blue™ hTLR4 (A) and Null2 (B) cells by protein 
samples of BW30270/pJexpress404:CYT-APOA1H6 and FreE coli™/pJexpress404:CYT-APOA1H6 strains
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LPS and Lipid IVA in HEK-Blue TLR4/MD-2 Assay
LPS 
32
Lipid IVA 
NF-κB Induction in HEK-Blue™ hTLR4/MD2 Assay by Purified ApoA1
From WT host
B.
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From FreE coli hosts
Expression and purification of VHm36:  Stimulation of HEK-Blue™ hTLR4 (A) and Null2 (B) cells by protein 
samples of BW30270/pJexpress404:CYT-VHM36H6 and FreE coli™/pJexpress404:CYT-VHM36H6 strains
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pUC18 Plasmid Isolated from ∆endA ∆recA FreE coli™ Strains
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DNA
Qiagen
MaxiPrep
LAL Assay
Stimulation of HEK-Blue™ hTLR4 cells by pUC18 plasmid DNA samples isolated from 
∆endA ∆recA derivatives of FreE coli™ strains
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What about Horseshoe Crabs?
LAL Assay Activities of LPS and Lipid IVA
Lipid IVA
Sample  
LAL
[EU/mg]
Lipid IVA 400,000
LPS (WT) 1,600,000
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LAL Assay Activities of Protein Samples
Host 
Strain
Protein
Protein 
conc
[mg/ml]
Protein 
yield 
[mg]
Total EU 
Sample   
EU/mg 
protein
38
BW30270 VHm36 5.2 10.3 150.0 15.00
KPM335 VHm36 1.8 3.6 1.6 0.43
BW30270 ApoA1 1.2 2.4 550.0 225.00
KPM335 ApoA1 2.0 4.1 230.0 57.00
LAL Activities of DNA Samples
Strain
Cult 
vol
[ml]
DNA 
[mg/ml]
DNA 
yield 
[µg]
Endotox
[EU/ml]
Total 
EU in 
prep
EU/mg 
DNA
XL1-Blue 100 0.86 430 290 140 340
XL1-Blue 400 1.4 700 2,800 1,400 2,000
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BW30270 
Δ(endArecA)
100 0.47 240 150 75 320
BW30270 
Δ(endArecA)
400 0.81 410 870 430 1,100
KPM353 100 0.37 190 0.11 0.055 0.29
KPM353 400 0.59 290 48 24 83
Summary
• The FreE coli™ strains are viable 
• Outer membrane is predominantly lipid IVA
• Inactivation of seven lipid A-related genes in
FreE coli™ strains precludes synthesis of 
- Normal LPS 
- Other TLR4-active lipid IVA derivatives
• Lipid IVA activity in LAL is significant
• BUT lipid IVA is readily removed by single column
• The FreE coli™ strains hold promise for manufacturing of 
endotoxin-free proteins and plasmid DNA.
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